Company news
Quantum Cyber N.V. news in 2025
Quantum Cyber N.V.'s news releases, calls and decks from 2025, newest first.
Mainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert to South America
November 17, 2025
Mainz Biomed Showcases Innovative Cancer Detection Solutions at MEDICA 2025
November 11, 2025
Mainz Biomed Reports Topline Results from Feasibility Study of Biomarker Panel in Pancreatic Cancer Project
October 7, 2025
Mainz Biomed Announces Commercial Launch of ColoAlert® in Switzerland
September 22, 2025
Mainz Biomed Announces Registration of ColoAlert in the United Kingdom
September 1, 2025
Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert®
August 12, 2025
Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants
August 3, 2025
Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for Health Insurance Companies
July 22, 2025
Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition
July 14, 2025
Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test
June 24, 2025
Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer Project
June 9, 2025
Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants
May 18, 2025
Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study
May 15, 2025
Mainz Biomed Enters into Technology Partnership with EDX Medical Group
April 28, 2025
Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval
April 27, 2025
Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update
March 31, 2025
Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study
March 26, 2025
Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer
March 12, 2025
Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month
February 10, 2025
Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements
January 26, 2025
Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population
January 20, 2025